QuiaPEG Pharmaceuticals Holding AB (QUIA) - Total Assets
Based on the latest financial reports, QuiaPEG Pharmaceuticals Holding AB (QUIA) holds total assets worth Skr15.28 Million SEK (≈ $1.64 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
QuiaPEG Pharmaceuticals Holding AB - Total Assets Trend (2008–2024)
This chart illustrates how QuiaPEG Pharmaceuticals Holding AB's total assets have evolved over time, based on quarterly financial data. Also see QUIA company net worth for the company's overall valuation and market capitalisation.
QuiaPEG Pharmaceuticals Holding AB - Asset Composition Analysis
Current Asset Composition (December 2024)
QuiaPEG Pharmaceuticals Holding AB's total assets of Skr15.28 Million consist of 4.6% current assets and 95.4% non-current assets. Review QuiaPEG Pharmaceuticals Holding AB debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0.0% |
| Accounts Receivable | Skr771.00K | 3.4% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr17.19 Million | 75.6% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how QuiaPEG Pharmaceuticals Holding AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See QUIA share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: QuiaPEG Pharmaceuticals Holding AB's current assets represent 4.6% of total assets in 2024, a decrease from 25.8% in 2008.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 16.0% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 75.0% of total assets, an increase from 22.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 75.6% of total assets.
QuiaPEG Pharmaceuticals Holding AB Competitors by Total Assets
Key competitors of QuiaPEG Pharmaceuticals Holding AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
QuiaPEG Pharmaceuticals Holding AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.09 | 0.55 | 1.84 |
| Quick Ratio | 0.09 | 0.55 | 1.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr-8.03 Million | Skr-3.57 Million | Skr8.18 Million |
QuiaPEG Pharmaceuticals Holding AB - Advanced Valuation Insights
This section examines the relationship between QuiaPEG Pharmaceuticals Holding AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.20 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -45.8% |
| Total Assets | Skr22.75 Million |
| Market Capitalization | $141.00K USD |
Valuation Analysis
Below Book Valuation: The market values QuiaPEG Pharmaceuticals Holding AB's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: QuiaPEG Pharmaceuticals Holding AB's assets decreased by 45.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for QuiaPEG Pharmaceuticals Holding AB (2008–2024)
The table below shows the annual total assets of QuiaPEG Pharmaceuticals Holding AB from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr22.75 Million ≈ $2.45 Million |
-45.78% |
| 2023-12-31 | Skr41.96 Million ≈ $4.52 Million |
+78.99% |
| 2022-12-31 | Skr23.44 Million ≈ $2.52 Million |
-1.35% |
| 2021-12-31 | Skr23.76 Million ≈ $2.56 Million |
+15.68% |
| 2020-12-31 | Skr20.54 Million ≈ $2.21 Million |
+35.07% |
| 2019-12-31 | Skr15.21 Million ≈ $1.64 Million |
+63.05% |
| 2018-12-31 | Skr9.33 Million ≈ $1.00 Million |
-26.70% |
| 2017-12-31 | Skr12.72 Million ≈ $1.37 Million |
-42.40% |
| 2016-12-31 | Skr22.09 Million ≈ $2.38 Million |
+148.76% |
| 2015-12-31 | Skr8.88 Million ≈ $955.63K |
-14.05% |
| 2014-12-31 | Skr10.33 Million ≈ $1.11 Million |
-10.13% |
| 2013-12-31 | Skr11.49 Million ≈ $1.24 Million |
-34.08% |
| 2012-12-31 | Skr17.44 Million ≈ $1.88 Million |
+0.38% |
| 2011-12-31 | Skr17.37 Million ≈ $1.87 Million |
-12.59% |
| 2010-12-31 | Skr19.88 Million ≈ $2.14 Million |
-3.84% |
| 2009-12-31 | Skr20.67 Million ≈ $2.22 Million |
-3.59% |
| 2008-12-31 | Skr21.44 Million ≈ $2.31 Million |
-- |
About QuiaPEG Pharmaceuticals Holding AB
Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as… Read more